We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
SELLAS Life Sciences Group Inc | NASDAQ:SLS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.09 | 7.03% | 1.37 | 1.37 | 1.38 | 1.35 | 1.21 | 1.25 | 1,274,119 | 00:59:06 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Large accelerated filer
|
|
¨
|
|
Accelerated filer
|
|
þ
|
Non-accelerated filer
|
|
¨
|
(Do not check if a smaller reporting company)
|
Smaller reporting company
|
|
¨
|
|
|
|
|
|
Title of each class of securities to be registered
|
Amount to be registered
|
Proposed maximum offering price per share
|
Proposed maximum aggregate offering price
|
Amount of registration fee
|
Common stock, par value $0.0001 per share
|
925,500 shares
(1)
|
$1.77
(2)
|
$1,638,135
(2)
|
|
Common stock, par value $0.0001 per share
|
40,000 shares
(1)
|
$1.83
(2)
|
$73,200
(2)
|
|
Common stock, par value $0.0001 per share
|
35,000 shares
(1)
|
$1.66
(2)
|
$58,100
(2)
|
|
Common stock, par value $0.0001 per share
|
350,000 shares
(1)
|
$1.68
(2)
|
$588,000
(2)
|
|
Common stock, par value $0.0001 per share
|
2,676,500 shares
(1)
|
$1.50
(2)
|
$4,014,750
(2)
|
|
Common stock, par value $0.0001 per share
|
105,000 shares
(1)
|
$0.84
(2)
|
$88,200
(2)
|
|
Common stock, par value $0.0001 per share
|
5,868,000 shares
(3)
|
$1.54
(4)
|
$9,036,720
4)
|
|
Total
|
10,000,000 shares
|
|
$15,497,105
|
$1,560.56
|
(1)
|
Represents shares issuable upon the exercise of outstanding stock options under the Galena Biopharma, Inc. Amended and Restated 2007 Incentive Plan, as amended (the "Plan"). Pursuant to Rule 416(a) of the Securities Act of 1933, this registration statement also covers such additional shares of common stock as may become issuable under the outstanding stock options in the event of a stock split, stock dividend, recapitalization or other similar change in the common stock.
|
(2)
|
Estimated solely for purposes of calculating the amount of registration fee pursuant to Rule 457(h)(1) of the Securities Act of 1933 based upon the exercise price of the outstanding stock options.
|
(3)
|
Represents shares reserved for issuance pursuant to the future awards under the Plan. Pursuant to Rule 416(a) of the Securities Act of 1933, this registration statement also covers such additional shares of common stock as may become issuable under the Plan in the event of a stock split, stock dividend, recapitalization or other similar change in the common stock.
|
(4)
|
Estimated solely for purposes of calculating the amount of registration fee pursuant to Rules 457(h)(1) and 457(c) of the Securities Act of 1933 based upon the $1.54 average of the high and low prices of Registrant’s common stock as reported on The NASDAQ Capital Market on April 15, 2016.
|
4.1
|
|
Galena Biopharma, Inc. (formerly, RXi Pharmaceuticals Corporation) Amended and Restated 2007 Incentive Plan (incorporated by reference to Annex A to the Registrant’s Proxy Statement on Schedule 14A filed on April 23, 2010).
|
|
|
|
4.2
|
|
Amendment to Galena Biopharma, Inc. Amended and Restated 2007 Incentive Plan (incorporated by reference to Annex A to the Registrant’s Proxy Statement on Schedule 14A filed on May 31, 2011).
|
|
|
|
4.3
|
|
Amendment to Galena Biopharma, Inc. Amended and Restated 2007 Incentive Plan (incorporated by reference to Annex A to the Registrant’s Proxy Statement on Schedule 14A filed on April 30, 2012).
|
|
|
|
4.4
|
|
Amendment to Galena Biopharma, Inc. Amended and Restated 2007 Incentive Plan (incorporated by reference to Annex B to the Registrant’s Proxy Statement on Schedule 14A filed on April 29, 2013).
|
|
|
|
4.5
|
|
Amendment to Galena Biopharma, Inc. Amended and Restated 2007 Incentive Plan (incorporated by reference to Annex B to the Registrant’s Proxy Statement on Schedule 14A filed on April 30, 2015).
|
|
|
|
5.1
|
|
Opinion of TroyGould PC (included with this registration statement).
|
|
|
|
23.1
|
|
Consent of Moss Adams LLP (included with this registration statement).
|
|
|
|
23.2
|
|
Consent of TroyGould PC (included in the opinion filed as Exhibit 5.1).
|
|
|
|
24.1
|
|
Power of Attorney (included on the signature page of this registration statement).
|
|
|
|
|
GALENA BIOPHARMA, INC.
|
|
|
|
By:
/s/ Mark W. Schwartz
|
|
Mark W. Schwartz, Ph.D.
|
|
President and Chief Executive Officer
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Mark W. Schwartz
|
|
President, Chief Executive Officer and Director (Principal Executive Officer)
|
|
April 19, 2016
|
Mark W. Schwartz, Ph. D.
|
|
|
|
|
|
|
|
|
|
/s/ John T. Burns
|
|
Controller
(Principal Accounting Officer)
|
|
April 19, 2016
|
John T. Burns
|
|
|
|
|
|
|
|
|
|
/s/ Sanford J. Hillsberg
|
|
Chairman of the Board
|
|
April 19, 2016
|
Sanford J. Hillsberg
|
|
|
|
|
|
|
|
|
|
/s/ William L. Ashton
|
|
Director
|
|
April 19, 2016
|
William L. Ashton
|
|
|
|
|
|
|
|
|
|
/s/ Richard Chin
|
|
Director
|
|
April 19, 2016
|
Richard Chin, M.D.
|
|
|
|
|
|
|
|
|
|
/s/ Irving M. Einhorn
|
|
Director
|
|
April 19, 2016
|
Irving M. Einhorn
|
|
|
|
|
|
|
|
|
|
/s/ Stephen S. Galliker
|
|
Director
|
|
April 19, 2016
|
Stephen S. Galliker
|
|
|
|
|
|
|
|
|
|
/s/ Steven A. Kriegsman
|
|
Director
|
|
April 19, 2016
|
Steven A. Kriegsman
|
|
|
|
|
|
|
|
|
|
/s/ Rudolph Nisi
|
|
Director
|
|
April 19, 2016
|
Rudolph Nisi, M.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Year SELLAS Life Sciences Chart |
1 Month SELLAS Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions